Company: MBIO
Filing Date: 2025-02-05
Form Type: S-1/A
Source: 0001104659-25-009408
Chunk: 18

Company: MUSTANG BIO, INC.
Filing Date: 2025-02-05
Form: S-1/A
Chunk 18
---
| ● | We or our licensors may be subject to costly and time-consuming litigation for infringement of third-party intellectual property rights or to enforce our or our licensors’ intellectual property rights against third-party infringers. |

| ● | Any dispute with our licensors may affect our ability to develop or commercialize our product candidates. |

Risks Relating to Our Control by Fortress Biotech, Inc. (“Fortress”)

| ● | Fortress controls a voting majority of our common stock and has the right to receive significant share grants annually, which will result in dilution of our other stockholders and could reduce the value of our common stock. |

| ● | We have entered into certain agreements with Fortress and may have received better terms from unaffiliated third parties. |

| ● | We share certain directors with Fortress, which could create conflicts of interest between us and Fortress. |

Risks Relating to this Offering

| ● | You will experience immediate dilution in the book value per share of the common stock purchased in the offering. |

| ● | If you purchase our securities in this offering, you may experience future dilution as a result of future equity offerings or other equity issuances. |

| ● | A substantial number of shares of common stock may be sold in the market following this offering, which may depress the market price for our common stock. |

| ● | We have broad discretion to determine how to use the funds raised in this offering and may use them in ways that may not enhance our operating results or the price of our common stock. |

| ● | There is no public market for the Warrants and pre-funded warrants being offered in this offering. |

| ● | The holders of Warrants and pre-funded warrants purchased in this offering will have no rights as common stockholders until such holders exercise their Warrants and pre-funded warrants and acquire shares of our common stock, except as set forth in the Warrants and pre-funded warrants. |

| ● | The Warrants are speculative in nature. |

| ● | The Warrants are not exercisable until stockholder approval, provided however, if the Pricing Conditions are met, the Warrants will be exercisable upon issuance. |

| ● | The market price for our common stock has been volatile and may continue to fluctuate or may decline significantly in the future. |

| ● | This is a “best efforts” offering, no minimum amount of securities is required to be sold, and we may not raise the amount of capital we believe is required for our business plans, including our